TKIs, Disease Progression and Subsequent Therapy in RCC

Opinion
Video

Key opinion leaders examine the application of tyrosine kinase inhibitors (TKIs) and evaluate first-line therapeutic approaches for renal cell carcinoma.

Recent Videos
Stacey A. Cohen, MD, and Daniel H. Ahn, DO, presenting slides
Stacey A. Cohen, MD, and Daniel H. Ahn, DO, presenting slides
2 KOLs are featured in this series
2 KOLs are featured in this series
Stacey A. Cohen, MD, and Daniel H. Ahn, DO, presenting slides
Stacey A. Cohen, MD, and Daniel H. Ahn, DO, presenting slides
Cesar Rodriguez, MD, and Frits van Rhee, MD, PhD
4 KOLs are featured in this panel.
4 KOLs are featured in this panel.
2 KOLs are featured in this series
Related Content